Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies

Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has conseque...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellis, Leigh, Pili, Roberto
Formato: Texto
Lenguaje:English
Publicado: MDPI 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000686/
https://www.ncbi.nlm.nih.gov/pubmed/21151768
http://dx.doi.org/10.3390/ph3082441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000686/
https://www.ncbi.nlm.nih.gov/pubmed/21151768
http://dx.doi.org/10.3390/ph3082441

Ejemplares similares